AUTL Autolus Therapeutics plc
Price (delayed)
$1.57
Market cap
$417.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.86
Enterprise value
$489.75M
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a
Highlights
The EPS has grown by 30% since the previous quarter and by 28% year-on-year
Autolus Therapeutics's quick ratio has surged by 81% YoY but it has decreased by 23% QoQ
Autolus Therapeutics's net income has increased by 18% QoQ but it has decreased by 6% YoY
The company's gross profit has shrunk by 175% YoY and by 113% QoQ
Autolus Therapeutics's gross margin has shrunk by 113% QoQ and by 113% YoY
Key stats
What are the main financial stats of AUTL
Market
Valuations
Earnings
Shares outstanding
266.13M
Market cap
$417.82M
Enterprise value
$489.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.98
Price to sales (P/S)
39.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.39
Revenue
$10.12M
Gross profit
-$1.27M
Operating income
-$241.21M
Net income
-$220.66M
EBIT
-$209.84M
EBITDA
-$197.41M
Free cash flow
-$228.35M
Per share
Balance sheet
Liquidity
EPS
-$0.86
EPS diluted
-$0.86
Free cash flow per share
-$0.89
Book value per share
$1.61
Revenue per share
$0.04
TBVPS
$3.02
Total assets
$782.73M
Total liabilities
$355.4M
Debt
$300.73M
Equity
$427.33M
Working capital
$600.19M
Debt to equity
0.7
Current ratio
10.88
Quick ratio
9.7
Net debt/EBITDA
-0.36
Margins
Efficiency
Dividend
EBITDA margin
-1,950.7%
Gross margin
-12.5%
Net margin
-2,180.5%
Operating margin
-2,383.5%
Return on assets
-26.2%
Return on equity
-43.8%
Return on invested capital
-42.6%
Return on capital employed
-29.1%
Return on sales
-2,073.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUTL stock price
How has the Autolus Therapeutics stock price performed over time
Intraday
11.35%
1 week
-3.68%
1 month
-9.25%
1 year
-71.51%
YTD
-33.19%
QTD
1.29%
Financial performance
How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$10.12M
Gross profit
-$1.27M
Operating income
-$241.21M
Net income
-$220.66M
Gross margin
-12.5%
Net margin
-2,180.5%
The company's gross profit has shrunk by 175% YoY and by 113% QoQ
Autolus Therapeutics's gross margin has shrunk by 113% QoQ and by 113% YoY
AUTL's net margin has soared by 82% year-on-year and by 19% since the previous quarter
AUTL's operating margin has surged by 77% year-on-year but it is down by 10% since the previous quarter
Growth
What is Autolus Therapeutics's growth rate over time
Valuation
What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
0.98
P/S
39.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.39
The EPS has grown by 30% since the previous quarter and by 28% year-on-year
AUTL's price to book (P/B) is 60% lower than its 5-year quarterly average of 2.2 and 56% lower than its last 4 quarters average of 2.0
Autolus Therapeutics's equity has decreased by 10% QoQ
AUTL's price to sales (P/S) is 83% lower than its 5-year quarterly average of 208.5 and 62% lower than its last 4 quarters average of 94.5
Efficiency
How efficient is Autolus Therapeutics business performance
The return on sales has surged by 78% year-on-year but it has declined by 4.7% since the previous quarter
The return on equity has surged by 59% year-on-year and by 31% since the previous quarter
Autolus Therapeutics's return on assets has increased by 47% YoY and by 28% QoQ
Autolus Therapeutics's ROIC has increased by 26% YoY and by 20% from the previous quarter
Dividends
What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUTL.
Financial health
How did Autolus Therapeutics financials performed over time
The company's total assets is 120% higher than its total liabilities
The company's total assets has surged by 109% YoY but it fell by 5% QoQ
Autolus Therapeutics's quick ratio has surged by 81% YoY but it has decreased by 23% QoQ
AUTL's debt is 30% smaller than its equity
The company's debt to equity has shrunk by 65% YoY but it rose by 11% QoQ
AUTL's debt is up by 34% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.